Valbiotis Valuation Multiples

Valbiotis Overview

About Valbiotis

Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.

Founded

2014

HQ

Employees

38

Website

valbiotis.com

Sectors

Nutraceuticals & CosmeceuticalsBioTech

Financials (LTM)

Revenue: $2M

EBITDA: ($10M)

EV

$24M

Valuation Multiples

Multiples.vc

Start free trial

Valbiotis Financials

Valbiotis reported last 12-month revenue of $2M and negative EBITDA of ($10M).

In the same LTM period, Valbiotis generated ($10M) in EBITDA losses and had net loss of ($11M).

Valbiotis P&L

In the most recent fiscal year, Valbiotis reported revenue of $1M and EBITDA of ($10M).

Valbiotis expects next 12-month revenue of XXX and NTM EBITDA of XXX

Valbiotis Stock Performance

Valbiotis has current market cap of $28M, and enterprise value of $24M.

Valbiotis' stock price is $1.20.

Valbiotis Valuation Multiples

Valbiotis trades at 10.4x EV/Revenue multiple, and (2.4x) EV/EBITDA.

Valbiotis Financial Valuation Multiples

As of April 19, 2026, Valbiotis has market cap of $28M and EV of $24M.

Equity research analysts estimate Valbiotis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Valbiotis has a P/E ratio of (2.7x).

Valbiotis Margins & Growth Rates

Valbiotis' revenue in the last 12 month grew by 280%.

Valbiotis' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.

Valbiotis' rule of 40 is 239% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Valbiotis' rule of X is 842% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Valbiotis Public Comps

See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.

Valbiotis M&A Activity

Valbiotis acquired XXX companies to date.

Last acquisition by Valbiotis was on XXXXXXXX, XXXXX. Valbiotis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Valbiotis Investment Activity

Valbiotis invested in XXX companies to date.

Valbiotis made its latest investment on XXXXXXXX, XXXXX. Valbiotis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).